Oxford BioDynamics - OBD develops multi-cancer diagnostic test for dogs

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
OBD
Oxford BioDynamics develops a high accuracy,
discriminating diagnostic test for multiple canine cancers
· EpiSwitch® Specific Canine Blood (EpiSwitch® SCB) test is a new canine multi-cancer diagnostic test based on OBD's non-invasive EpiSwitch® array platform
· Test developed in collaboration with leading US KOL Professor Jaime F Modiano, University of Minnesota, USA
· Test offers early blood-based detection and discrimination of six high-utility, frequently occuring cancer types: three sarcomas, two lymphomas, and malignant melanoma, each with balanced accuracy of >89%
· Real-world utility data with selected veterinary services will further validate the test
The test was developed in collaboration with Veterinary Referral Associates, Gaithersburg MD, USA; Animal Cancer Care and Research Program, University of Minnesota,
OBD's EpiSwitch® SCB ("Scooby") test is a well balanced, highly accurate blood test to specifically diagnose canine diffuse large B-cell lymphoma (DLBCL), T-zone lymphoma (TZL), hemangiosarcoma (HSA), histiocytic sarcoma, osteosarcoma, and canine malignant melanoma, in a powerful single assay format. The test was validated using 3D whole-genome profiling in peripheral blood. It demonstrated high sensitivity and specificity for lymphomas and sarcomas as a class (accuracy >80%); and high sensitivity and specificity for specific individual indications, with an accuracy >89%. The validation results are published in BioRxiv (link here).
There is a critical need in veterinary oncology for an accurate, specific, sensitive, non-invasive (blood) biomarker assay to assess canine oncological indications earlier, to better inform therapeutic interventions. Current alternatives for non-invasive canine cancer detection deliver only a "cancer/no cancer" outcome, with low specificity and no distinction between different cancer types. Effective therapeutic intervention requires a definitive identification of a specific cancer type - often a difficult task in current veterinary practice.
OBD's newly published study demonstrates a novel 3D genomic approach that can diagnose six canine cancers, as well as support continuing upgrade for additional diagnostic profiles, in a modular manner. The EpiSwitch® SCB test promises to help veterinary specialists to diagnose the disease, make more informed treatment decisions, minimize or avoid unnecessarily toxicity, and efficiently manage costs and resources.
EpiSwitch SCB will be made available to a select group of vets who will generate real-world utility data that will further validate the test. It is expected that the commercialisation of the EpiSwitch ECB test will be through a partnership or outlicensing arrangement with an organisation with an existing presence in the pet healthcare market.
Dr
Professor
Dr Alexandre Akoulitchev, CSO, OBD said: "EpiSwitch SCB combines all the advantages of EpiSwitch blood based biomarkers with a novel proprietary multi-choice EpiSwitch array design. Once again, we were determined to translate to practice the full potential of our EpiSwitch technology, this time to tackle a prevalent veterinary challenge in support of our four legged friends."
Reference
bioRxiv 2024.05.22.595358; doi: https://doi.org/10.1101/2024.05.22.595358
Whole Genome 3D Blood Biopsy Profiling of Canine Cancers: Development and Validation of EpiSwitch Multi-Choice Array-Based Diagnostic Test.
- Ends -
For further details please contact:
|
Oxford BioDynamics Plc
|
+44 (0)1865 518910 |
|
Shore Capital
|
+44 (0)20 7408 4090 |
|
WG Partners (Joint Broker to OBD)
|
+44 (0)20 3705 9330 |
|
Instinctif Partners
|
Tel: +44 (0)20 7457 2020 OxfordBioDynamics@instinctif.com |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
It has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, launched in the US and
The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring, in a wide range of indications, including oncology, neurology, inflammation, hepatology and animal health.
In
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.
OBD's group headquarters and research, product development and
The company is listed on the London Stock Exchange's AIM, with ticker OBD. For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on Twitter (@OxBioDynamics) and LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE